The DILI-sim Initiative is a consortium of life science companies who are dedicated to improving patient safety, reducing the need for animal testing, and decreasing the costs and time necessary to bring new therapies to market. Developing the DILIsym® software is one of the goals of the DILI-sim Initiative.
DILIsym® is a multi-scale computational model of drug-induced liver injury (DILI). The software is designed for use during drug development to ensure an enhanced understanding of the DILI hazard posed by individual molecules and to provide deeper insight into the mechanisms responsible. To support the DILIsym® software, DILIsym Services have teamed up with Cyprotex for the provision of high quality in vitro data and toxicology expertise.
Cyprotex is able to provide the following key DILIsym® inputs for representations of mitochondrial dysfunction, oxidative stress, and lipotoxicity:
Mitochondrial function assay with the Agilent Seahorse XFe96 Analyzer to provide data such as oxygen consumption rate (OCR) and extracellular acidification rate (ECAR).
Cell health parameters using high content imaging with markers such as oxidative stress or reactive oxygen species (ROS), glutathione (GSH), mitochondrial membrane potential, ATP and steatosis.
Mass spectrometry analytical services to assess intracellular concentrations for each assay.
As well as providing an indication of DILI risk, DILIsym® simulation results also help with selection of future in vitro assays to be completed, making the data collection / simulation cycle iterative.
Download our joint poster illustrating the value of using Cyprotex data for DILIsym® predictions.